CClinicalTrials.gg
Sign In
Status unknownNCT02254824Updated Oct 2, 2014

Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients

A Phase 4 interventional study of Xuezhikang and Atorvastatin in Hypertension, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

Read the detailed description

EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin on vascular function protection in hypertensive patients at low/moderate cardiovascular risk.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Xuezhikang
  • atorvastatin
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's planned enrollment of 300 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 141 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China

Exclusion criteria

Exclusion Criteria:

  • Secondary Hypertension
  • Women who are pregnant or lactating
  • History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy
  • Type 2 Diabetes
  • Active liver disease or impaired liver function tests
  • Impaired renal function
  • Uncontrolled cardiac arrhythmia
  • Patient who is unable to give informed consent
  • Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Normal-dose statin

    Lifestyle modification with Normal-dose statin

    Drug: Atorvastatin · Behavioral: Lifestyle modification

  • Active comparator
    Lifestyle modification + Xuezhikang

    Lifestyle changes with Xuezhikang

    Drug: Xuezhikang · Behavioral: Lifestyle modification

  • Active comparator
    Lifestyle modification

    Lifestyle modification

    Behavioral: Lifestyle modification

Interventions

  • DrugXuezhikang

    Xuezhikang

  • DrugAtorvastatin

    Atorvastatin

  • BehavioralLifestyle modification

    Lifestyle modification

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the Flow Mediated Dilatation (FMD)

    Time frame: 1 year

Secondary outcomes

  1. the carotid - femoral Pulse Wave Velocity (cf-PWV),

    Time frame: 1 year

  2. inflammatory markers

    Time frame: 1 year

  3. lipid profiles

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital
    Beijing, Beijing 100037, China
    • Naqiang Lv, Doctor · Contact · lvnaqiang@gmail.com · 0086-10-13466500331
    • Aimin Dang, Doctor · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02254824
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborators
Peking University First Hospital, Peking Union Medical College Hospital, Beijing Hospital of Traditional Chinese Medicine
Responsible party
Aimin Dang (Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Oct 2, 2014
Start date
Oct 2013
Primary completion
Oct 2015 (estimated)
Completion
Oct 2016 (estimated)
Last update
Oct 2, 2014

Study contacts

Aimin - Dang, Doctor
Contact
amdang@fuwaihospital.org
0086-10-88398155
Aimin Dang, Doctor
principal investigator · Fuwai Hospital & Cardiovascular Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension→

Other studies from this sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Start the discussion